BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15885814)

  • 1. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
    Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
    Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
    Ueno T; Mitsuya H
    Biochemistry; 1997 Feb; 36(5):1092-9. PubMed ID: 9033399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
    Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
    J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.
    Tamalet C; Yahi N; Tourrès C; Colson P; Quinson AM; Poizot-Martin I; Dhiver C; Fantini J
    Virology; 2000 May; 270(2):310-6. PubMed ID: 10792990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.
    Sharma PL; Nurpeisov V; Lee K; Skaggs S; Di San Filippo CA; Schinazi RF
    Virology; 2004 Apr; 321(2):222-34. PubMed ID: 15051383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
    Maldonado JO; Mansky LM
    Viruses; 2018 Jul; 10(7):. PubMed ID: 30029500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
    Feng JY; Anderson KS
    Biochemistry; 1999 Jul; 38(29):9440-8. PubMed ID: 10413520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues.
    Deval J; Selmi B; Boretto J; Egloff MP; Guerreiro C; Sarfati S; Canard B
    J Biol Chem; 2002 Nov; 277(44):42097-104. PubMed ID: 12194983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach.
    Chong Y; Borroto-Esoda K; Furman PA; Schinazi RF; Chu CK
    Antivir Chem Chemother; 2002 Mar; 13(2):115-28. PubMed ID: 12238529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.
    Furman PA; Jeffrey J; Kiefer LL; Feng JY; Anderson KS; Borroto-Esoda K; Hill E; Copeland WC; Chu CK; Sommadossi JP; Liberman I; Schinazi RF; Painter GR
    Antimicrob Agents Chemother; 2001 Jan; 45(1):158-65. PubMed ID: 11120959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
    Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.
    Ueno T; Shirasaka T; Mitsuya H
    J Biol Chem; 1995 Oct; 270(40):23605-11. PubMed ID: 7559526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.
    Chong Y; Chu CK
    Antiviral Res; 2004 Jul; 63(1):7-13. PubMed ID: 15196815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.